A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)

ClinicalTrials.gov ID: NCT07073547

Public ClinicalTrials.gov record NCT07073547. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 14, 2026, 5:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Modular, Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120, a Dual-targeting Autologous Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against BCMA and CD19 in Participants With Multiple Myeloma (DURGA-2)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is an interventional, modular, open-label, multicenter study to primarily evaluate the safety and tolerability of AZD0120 in adult participants with multiple myeloma (MM).

Study identification

NCT ID: NCT07073547
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: AstraZeneca; Industry
Enrollment: 40 participants

Conditions and interventions

Conditions

Multiple Myeloma

Interventions

AZD0120 Biological

Biological

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 30, 2025
Primary completion: May 25, 2028
Completion: May 25, 2028
Last update posted: Jul 12, 2026

2025 – 2028

United States locations

U.S. sites: 13
U.S. states: 12
U.S. cities: 13

Facility	City	State	ZIP	Site status
Research Site	Phoenix	Arizona	85054	Withdrawn
Research Site	Duarte	California	91010	Recruiting
Research Site	Denver	Colorado	80218	Recruiting
Research Site	Tampa	Florida	33612	Recruiting
Research Site	Atlanta	Georgia	30322	Recruiting
Research Site	Iowa City	Iowa	52242	Recruiting
Research Site	Rochester	Minnesota	55905	Withdrawn
Research Site	St Louis	Missouri	63110	Recruiting
Research Site	New York	New York	10016	Recruiting
Research Site	Nashville	Tennessee	37203	Recruiting
Research Site	Dallas	Texas	75235	Withdrawn
Research Site	Houston	Texas	77030	Recruiting
Research Site	Charlottesville	Virginia	22903	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07073547, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 12, 2026 · Synced Sep 14, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07073547 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →